New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
11:51 EDTLL, SRPT, OREX, MBI, FTNT, INFN, STX, AVP, GNCOptions with increasing implied volatility:
Options with increasing implied volatility: LL SRPT OREX MBI FTNT INFN STX AVP GNC
News For LL;SRPT;OREX;MBI;FTNT;INFN;STX;AVP;GNC From The Last 14 Days
Check below for free stories on LL;SRPT;OREX;MBI;FTNT;INFN;STX;AVP;GNC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 11, 2014
10:20 EDTSRPTNebraska Medical Center not naming Ebola drug, The Street reports
Nebraska Medical Center is not releasing the name of the experimental Ebola drug being given to Dr. Rick Sacra, The Street's Adam Feuerstein reports, citing an emailed response from the hospital. Traders are speculating Tekmira (TKMR) is the manufacturer of the drug, Feuerstein points out. Sarepta (SRPT) disclosed that it is not involved in the treatment of Sacra, added Feuerstein. Shares of Tekmira are up 3% to $19.65 in morning trading. Reference Link
08:01 EDTOREXOrexigen Contrave could have stronger launch than peers, says Wells Fargo
After the FDA approved Orexigen's (OREX) Contrave as a treatment option for chronic weight management, Wells Fargo does not believe the label included any significant surprises. The firm thinks multiple factors increase the chances that Contrave's launch will be stronger than two other weight loss drugs that were launched in recent years by VIVUS and Arena Pharmaceuticals (ARNA). The firm keeps an Outperform rating on Orexigen.
07:06 EDTOREXOrexigen's Contrave weight management tablets approved by FDA
Orexigen Therapeutics and Takeda Pharmaceuticals U.S.A. jointly announced that the FDA has approved Contrave extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index indicating obese or overweight, in the presence of at least one weight-related comorbid condition. Takeda is planning to commercially launch Contrave in the fall.
06:49 EDTOREXFDA approves weight management drug Contrave
The U.S. Food and Drug Administration yesterday approved Contrave as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. The drug is approved for use in adults with a body mass index of 30 or greater or adults with a BMI of 27 or greater who have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Contrave is a combination of two FDA-approved drugs, naltrexone and bupropion, in an extended-release formulation. The effectiveness of Contrave was evaluated in multiple clinical trials that included approximately 4,500 obese and overweight patients with and without significant weight-related conditions treated for one year. Contrave is distributed by Takeda Pharmaceuticals America (TKPYY) for Orexigen Therapeutics (OREX).
September 10, 2014
18:27 EDTOREXOrexigen trading halted, pending news
Subscribe for More Information
08:02 EDTSTXSeagate says has shipped 10 millionth solid state hybrid hard drive
Subscribe for More Information
September 9, 2014
15:27 EDTOREXOrexigen volatility elevated
Subscribe for More Information
12:46 EDTOREXNovo Nordisk weight loss drug helped people get thinner, Bloomberg reports
Subscribe for More Information
10:10 EDTAVPOn the Fly: Analyst Downgrade Summary
Subscribe for More Information
10:10 EDTAVPOn the Fly: Analyst Upgrade Summary
Subscribe for More Information
09:12 EDTAVPOn The Fly: Pre-market Movers
Subscribe for More Information
08:14 EDTAVPAvon Products downgraded to Neutral from Buy at Citigroup
Subscribe for More Information
07:42 EDTAVPAvon Products upgraded to Buy from Neutral at BTIG
BTIG upgraded Avon to Buy with a $17 price target based on valuation, easy comps, U.S. profitability, and strategic initiatives.
September 8, 2014
17:25 EDTAVPBaker Hughes names Kimberly Ross CFO
Baker Hughes (BHI) announced that Kimberly A. Ross, has been appointed senior vice president and CFO effective October 22. Ross currently serves as executive vice president and CFO of Avon Products (AVP).
17:22 EDTOREXOrexigen, Takeda Pharmaceutical in services agreement
Orexigen disclosed in a regulatory filing that in preparation for the potential launch of NB32, Orexigen Therapeutics (OREX) and Takeda Pharmaceutical Company (TKPYY) entered into a Manufacturing Services Agreement, dated September 2, in accordance with the Collaboration Agreement between the company and Takeda, effective as of September 1, 2010, as amended by Amendment Number 1 to Collaboration Agreement effective as of September 26, 2013. Pursuant to the Agreement, among other things, the company will supply to Takeda, and Takeda will, subject to certain exceptions as set forth in the Agreement and Collaboration Agreement, exclusively purchase from the Company, all of Takeda’s requirements of NB32 for commercialization in the United States, Canada and Mexico during the term of the Collaboration Agreement. The Agreement will continue in full force and effect until the expiration or termination of the Collaboration Agreement.
17:19 EDTAVPAvon Products announces CFO Kimberly Ross resigns, effective October 2
Avon Products announced that Kimberly Ross, Executive Vice President and CFO, has resigned effective October 2. Ross joined Avon in 2011. Robert Loughran, Vice President and Corporate Controller, will be appointed Avon's acting CFO effective October 2, while the company completes the search process for a permanent CFO.
14:30 EDTSTXSeagate volatility low into strategic update
Subscribe for More Information
10:06 EDTINFNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:12 EDTINFNOn The Fly: Pre-market Movers
Subscribe for More Information
05:33 EDTINFNInfinera upgraded to Buy from Hold at Jefferies
Jefferies upgraded Infinera to Buy on expectations the company's pending metro WDM product line will successful. The firm notes the product line will be at the company's September 18 analyst meeting. Jefferies raised its price target for shares to $14 from $10.50.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use